Advanced Ovarian Cancer: Weighing the Risks and Benefits of Surgery

Amanika Kumar, William A. Cliby

Research output: Contribution to journalArticle

Abstract

Treatment for patients with advanced ovarian cancer includes a combination of platinum-based chemotherapy and maximally cytoreductive surgery. The 2 options for initial treatment include upfront surgery followed by adjuvant chemotherapy or neoadjuvant chemotherapy followed by interval surgery. Deciding between which approach is a on the basis of several factors: (1) resectability of disease; (2) patient factors such as age, albumin, and body mass index; (3) patient wishes; and (4) overall functional status. Research is needed to further refine these approaches and create a patient-focused treatment plan which includes novel factors such as molecular subtype of disease and frailty and sarcopenia.

Original languageEnglish (US)
Pages (from-to)74-79
Number of pages6
JournalClinical Obstetrics and Gynecology
Volume63
Issue number1
DOIs
StatePublished - Mar 1 2020

    Fingerprint

Keywords

  • cytoreduction
  • frailty
  • ovarian cancer
  • residual disease
  • surgery
  • surgical risk prediction

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this